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Connectivity of Radiotracers to Vasodilators
Is Thallium the Missing Link?*
Vasken Dilsizian, MD
Baltimore, MarylandIn clinical practice, when new radiotracers receive
U.S. Food and Drug Administration approval,
there is a tendency to presume that comparable
sensitivity and specificity for the detection of coro-
nary artery disease (CAD) between radiotracers, for
example, thallium and sestamibi, extends to other
clinically and prognostically relevant parameters,
such as comparable size and severity of perfusion
defects on stress (summed stress score) and extent
See page 1198
of reversibility when compared with rest images
(summed difference score). Although 2 radiotracers
may show a perfusion defect in a particular coronary
artery vascular territory with stress, the size and sever-
ity of the defect and the extent of defect reversibility
may be significantly different depending on the extrac-
tion fraction of the radiotracer and the point of the
plateau phase at higher blood flow rates. Such data are
generally not captured when using only sensitivity and
specificity and coronary angiography as the reference
standard for detecting CAD.
Clinical and Prognostic Relevance
of Myocardial Perfusion Defect Size
and Reversibility
The extent and severity of reversible myocardial
perfusion defects has been repeatedly shown to be
an independent variable in predicting subsequent
cardiac events in the literature. Among patients
with suspected CAD and no prior myocardial
infarction who were followed up for 1 year after
*Editorials published in JACC: Cardiovascular Imaging reflect the views of
the authors and do not necessarily represent the views of JACC: Cardio-
vascular Imaging or the American College of Cardiology.From the University of Maryland School of Medicine, Baltimore,
Maryland.myocardial perfusion imaging, stepwise logistic re-
gression identified only 3 independent predictors of
subsequent cardiac events: 1) the number of regions
with reversible defects (extent of myocardial isch-
emia); 2) the magnitude of hypoperfusion (severity of
the perfusion defect); and 3) the achieved heart rate
(reflecting the exercise workload) (1). The cardiac
event rate increased in a curvilinear fashion as a
function of extent and severity of reversible defects.
It has been well established that all 3 clinically
approved and available single-photon emission
computed tomography (SPECT) radiotracers (thal-
lium, Tc-99m–labeled sestamibi and tetrofosmin)
can differentiate patients showing normal perfusion
at peak stress with 1% annual rate of death or
infarction from those with abnormal myocardial
perfusion scans with event rates that are in propor-
tion to the extent and severity of ischemia and scar.
Whether the extent and severity of perfusion de-
fects among subjects with abnormal scans is variable
among the 3 radiotracers has not been well studied
in the literature. The latter distinction becomes
clinically pertinent, however, if coronary artery re-
vascularization is being contemplated for purposes
of improving prognosis. The extent and severity of
myocardial ischemia can guide whether the patient’s
risk is high enough to warrant revascularization.
Such a risk-based approach for medical or revascu-
larization therapy requires accurate determination
of the true extent of underlying myocardial perfu-
sion defect and its reversibility.
Efﬁcacy Studies of Vasodilators With
SPECT Radiotracers
In the case of the recently approved adenosine
receptor subtype A2A-selective agonist, regadeno-
son, among 2,015 patients from 2 identical double-
blind, randomized, multicenter phase 3 ADVANCE
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1210ADenoscan Versus regAdenosoN Comparative
valuation for Myocardial Perfusion Imaging) trials,
egadenoson administered as a fixed-unit bolus was
hown to be noninferior to adenosine infusion for the
etection of reversible defects (2). Given that the aim
f the ADVANCE trial was to test the efficacy of the
asodilators and not the radiotracers, it was appropri-
te for subjects to receive the same radiotracer(s) in the
denosine–adenosine and adenosine–regadenoson
omparison to limit other confounding variables, such
s differences in the biodistribution and extraction
raction of the radiotracers. Because all 3 clinically
vailable SPECT radiotracers were used in the trials, it
as been generally assumed that there are no differ-
nces among these 3 radiotracers when used with
egadenoson for detection of coronary artery disease or
or assessment of the extent and severity of relative
erfusion defects. The latter, however, was not tested
n the clinical trial.
In this issue of iJACC, Mekkaoui et al. (3)
ompare the vasodilatory effects of regadenoson
ith adenosine in clinically relevant instrumented
anine models, using thallium and sestamibi as the
adiotracers. Similar to adenosine infusion, the
nvestigators found that bolus injection of regade-
oson produced comparable hemodynamics effects
Figure 1. Underestimation of Myocardial Blood Flow by SPECT
Bar graphs showing mean microsphere ﬂow, thallium, and sestamib
ratios for critical coronary artery stenosis with adenosine (left) and
cantly underestimate blood ﬂow when compared with microsphere
mibi when compared with thallium (3,6). Similar results are obtaine
tetrofosmin, in comparison with thallium and microsphere with ade
Mekkaoui et al. (3), Glover et al. (6), and Glover et al. (7). SPECT  singlnd similar biodistribution and clearance kinetics of
hallium and sestamibi. The arterial blood clearance
alf times with regadenoson and adenosine were
ignificantly faster for sestamibi (mean 1.4 to 1.5
in) than for thallium (mean 2.5 to 2.7 min),
hich may have implications on the duration of
asodilator stressors when using thallium as the
adiotracer. However, despite the differences in
lood clearance, thallium performed better as a
erfusion agent than sestamibi for the detection of
elative flow heterogeneity with regadenoson, as
efined by ex vivo SPECT and well counting
echniques. Although both radiotracers underesti-
ated the true myocardial blood flow heterogeneity
hen compared with microspheres, part of the
nderestimation of thallium could be attributed to
he 15-min time delay between injection of thal-
ium and assessment of myocardial uptake, allowing
or the well-recognized phenomenon of thallium
edistribution to take place. In contrast, the under-
stimation of sestamibi likely reflects its lower
xtraction fraction when compared with thallium
ather than tracer redistribution (Fig. 1).
On the basis of these experimental findings, the
nvestigators suggest that thallium may offer a
linical advantage over the Tc-99m–labeled perfu-
iotracers When Compared With Microspheres
tivities expressed as the stenotic-to-normal thallium and sestamibi
denoson (middle). Although both thallium and sestamibi signiﬁ-
, the degree of underestimation is signiﬁcantly greater for sesta-
ing a different technetium-99m–labeled perfusion tracer,
ine (right) (7). Adapted and reprinted, with permission, fromRad
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1211ion tracers. The more linear myocardial uptake of
hallium during regadenoson vasodilation than ses-
amibi may have clinical implications regarding the
xtent and severity of myocardial perfusion defects
nd for predicting future cardiac events. If these
ifferences in myocardial flow heterogeneity and
efect size with thallium and sestamibi are repro-
uced with regadenoson in the clinical setting, it
ould be important to revisit using thallium proto-
ols in clinical practice, especially among patients
ho weigh 220 lbs.
xperimental and Clinical Evidence for
nderestimation of Flow Disparity With
c-99m–Labeled Radiotracers
n ideal radiotracer must have high first-pass extrac-
ion by the heart (50%) and rapid clearance from the
lood (clearance half time of5min). The radiotracer
hat most closely parallels myocardial blood flow
ould be expected to most accurately identify CAD.
he extraction fraction of thallium is approximately
5%, whereas that of sestamibi is near 60%. Because
he extraction of sestamibi is less than that of thallium
t resting flow rates, further decreases in extraction at
igher flows (2 ml·min1·g1), as with pharmaco-
ogic vasodilatation, may lead to an underestimation of
he size and magnitude of perfusion defects when
ompared with thallium (4).
Using vasodilator stimulation in canines, Leon
t al. (5) compared the extent of myocardial
erfusion defect size with thallium and sestamibi
sing post-mortem staining to define the extent
f the hypoperfused region. When coronary ar-
ery occlusion was near total, sestamibi and thal-
ium showed similar defect contrast and areas. How-
ver, when coronary artery occlusion was moderate,
ounts in the defects were 39% higher for sestamibi
ompared with the thallium defects, and the area of
he sestamibi defects occupied only 37% of the area of
he defect on the thallium images. The extent of
ypoperfused myocardium determined pathologically
as closer to the thallium than the sestamibi defect
ize (5).
Similar underestimation of the true myocardial
lood flow deficit was reported in canine models
ith critical and mild coronary artery stenosis,
uthanized 5 min after the injection of thallium and
estamibi (6). Although myocardial uptake of both
hallium and sestamibi seemed to plateau at high
oronary flow rates, the extent of underestimation
f coronary blood flow was statistically greater with
estamibi (leveling off approximately 2 normal flow), pesulting in limited contrast between normal and
tenotic myocardium (Fig. 1). When the coronary
rtery stenosis was severe, the ratios of stenotic to
ormal activity by well counting for thallium (0.37 
.05) and sestamibi (0.53 0.06) underestimated the
icrosphere-determined flow disparity (0.17  0.03)
p  0.005), but the degree of underestimation was
reater for sestamibi (p 0.001). Similar results were
btained using a different technetium-99m–labeled
erfusion tracer, tetrofosmin, in comparison with
hallium and microsphere (7) (Fig. 1). Such underes-
imation of flow disparity with sestamibi and tetrofos-
in persisted (in comparison with thallium and mi-
rospheres), even when milder degrees of coronary
rtery stenosis were applied (6,7).
In large clinical studies, the sensitivity and
pecificity of thallium and sestamibi were shown
o be comparable for the detection of CAD.
owever, beyond detection of CAD, whether the
yocardial perfusion defect size, severity, and
eversibility are also similar between thallium and
estamibi remains controversial. When sestamibi
nd thallium were injected in the same subjects
uring stress, sestamibi myocardial perfusion
efects were consistently smaller than thallium
egardless of whether the sestamibi images were
cquired 120 min (8) or 60 min post-stress (9).
atients undergoing symptom-limited exercise
tress testing showed smaller sestamibi defect
izes than with stress thallium imaging (42 
9.9 g vs. 52  46.2 g, p  0.05) (8). Similar
nderestimation of defect size was obtained by
ther investigators when tetrofosmin was used
instead of sestamibi) as the comparator with
hallium (10).
onclusions
election of the ideal radiotracer with a pharma-
ologic vasodilator requires in-depth understand-
ng of the physical and physiological properties of
he radiotracer, the vasodilator, the interconnec-
ivity between the two, and the SPECT camera.
ith the advent of high-speed SPECT cameras,
ower doses of thallium (2.0 to 2.5 mCi) can now
rovide excellent image quality with a radiation
urden that is similar to that of technetium-
9m– based myocardial perfusion protocols
11,12). Thus, the weakest link for the connec-
ivity of radiotracers with vasodilators may rest in
he extraction fraction of the radiotracer and the
oint of the plateau phase at higher blood flow
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1212ates. Whether thallium will perform better than
estamibi in the clinical setting, as a perfusion
gent, for the detection of relative flow hetero-
eneity with regadenoson and for defect revers-Med 1997;38:1847–56.
9. Maublant JC, Marc
et al. Comparisoneprint requests and correspondence: Dr. Vasken
ilsizian, University of Maryland Medical Center,
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